Insulin receptor expression was found to be higher in HER-2+ tumor cells, which suggests that tumor budding not only predicts insulin receptor status, but also that the combination of HER-2 inhibitors and insulin receptor blockers (or metformin) may provide a potential treatment for patients with tumor budding at the corresponding grade in the future. This evidence concerns the gene ERBB2 and neoplasm.